External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>The opportunity for IDT to establish itself as a significant player in mRNA drug manufacture in Australia has diminished in recent months.</li><li>Last month Pfizer’s mRNA vaccine partner BioNTech agreed a Letter of Intent with the Victorian government to establish an mRNA Research Centre and clinical-scale manufacturing facility in IDT’s home state.</li><li>In addition, last week CSL in-licenced mRNA vaccine technology from Arcturus Therapeutics, including flu and a Phase III covid vaccine.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The opportunity for IDT to establish itself as a significant player in mRNA drug manufacture in Australia has diminished in recent months.Last month Pfizer’s mRNA vaccine partner BioNTech agreed a Letter of Intent with the Victorian government to establish an mRNA Research Centre and clinical-scale manufacturing facility in IDT’s home state.In addition, last week CSL in-licenced mRNA vaccine technology from Arcturus Therapeutics, including flu and a Phase III covid vaccine.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IDTオーストラリア（IDT） - BioNTechとCSLの買収によりRNAのビジネスチャンスが縮小

IDT Australia

IDTオーストラリア（IDT） - BioNTechとCSLの買収によりRNAのビジネスチャンスが縮小